Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

William G. Richards, Ph.D.

Co-Author

This page shows the publications co-authored by William Richards and Raphael Bueno.
Connection Strength

5.582
  1. Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma. J Thorac Oncol. 2021 Jul 06.
    View in: PubMed
    Score: 0.249
  2. Association of RERG Expression with Female Survival Advantage in Malignant Pleural Mesothelioma. Cancers (Basel). 2021 Feb 02; 13(3).
    View in: PubMed
    Score: 0.242
  3. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J Pathol. 2021 01; 253(1):68-79.
    View in: PubMed
    Score: 0.237
  4. Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). J Thorac Oncol. 2020 11; 15(11):1748-1757.
    View in: PubMed
    Score: 0.233
  5. Interobserver Variability of Quantitative and Qualitative Assessment Using MRI in Malignant Pleural Mesothelioma. Radiol Cardiothorac Imaging. 2020 Apr; 2(2):e190066.
    View in: PubMed
    Score: 0.229
  6. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer. 2019 Dec 01; 125(23):4164-4171.
    View in: PubMed
    Score: 0.218
  7. Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. J Natl Cancer Inst. 2018 03 01; 110(3):258-264.
    View in: PubMed
    Score: 0.197
  8. Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues. J Mol Diagn. 2017 01; 19(1):65-71.
    View in: PubMed
    Score: 0.181
  9. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016 12; 4(12):1038-1048.
    View in: PubMed
    Score: 0.181
  10. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016 Apr; 48(4):407-16.
    View in: PubMed
    Score: 0.172
  11. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res. 2016 Jan 15; 76(2):319-28.
    View in: PubMed
    Score: 0.168
  12. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg. 2014 Oct; 260(4):577-80; discussion 580-2.
    View in: PubMed
    Score: 0.156
  13. Gene expression ratio test distinguishes normal lung from lung tumors in solid tissue and FNA biopsies. J Mol Diagn. 2014 Mar; 16(2):267-72.
    View in: PubMed
    Score: 0.148
  14. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res. 2013 May 01; 19(9):2493-502.
    View in: PubMed
    Score: 0.140
  15. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013 Apr; 145(4):955-963.
    View in: PubMed
    Score: 0.139
  16. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2011 Aug; 40(2):298-303.
    View in: PubMed
    Score: 0.121
  17. Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2011 Jan 15; 17(2):310-6.
    View in: PubMed
    Score: 0.119
  18. Second generation sequencing of the mesothelioma tumor genome. PLoS One. 2010 May 13; 5(5):e10612.
    View in: PubMed
    Score: 0.115
  19. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer. 2010 Mar 15; 116(6):1510-7.
    View in: PubMed
    Score: 0.114
  20. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009 May 06; 101(9):678-86.
    View in: PubMed
    Score: 0.107
  21. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3521-6.
    View in: PubMed
    Score: 0.099
  22. A microaliquoting technique for precise histological annotation and optimization of cell content in frozen tissue specimens. Biotech Histochem. 2007 Aug; 82(4-5):189-97.
    View in: PubMed
    Score: 0.095
  23. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006 Apr 01; 24(10):1561-7.
    View in: PubMed
    Score: 0.086
  24. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005 Jun 15; 11(12):4406-14.
    View in: PubMed
    Score: 0.082
  25. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005 Jun; 166(6):1827-40.
    View in: PubMed
    Score: 0.082
  26. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev. 2003 Sep; 12(9):905-10.
    View in: PubMed
    Score: 0.072
  27. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 2003 Apr 16; 95(8):598-605.
    View in: PubMed
    Score: 0.070
  28. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002 Sep 01; 62(17):4963-7.
    View in: PubMed
    Score: 0.067
  29. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis. 2002 Jun; 23(6):1017-24.
    View in: PubMed
    Score: 0.066
  30. Detection and quantification of SV40 large T-antigen DNA in mesothelioma tissues and cell lines. Oncol Rep. 2002 May-Jun; 9(3):631-4.
    View in: PubMed
    Score: 0.066
  31. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg. 2000 Dec; 70(6):1826-31.
    View in: PubMed
    Score: 0.060
  32. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma. J Thorac Oncol. 2021 01; 16(1):89-103.
    View in: PubMed
    Score: 0.059
  33. Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2021 Apr; 161(4):1510-1518.
    View in: PubMed
    Score: 0.058
  34. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.055
  35. Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma. Mol Carcinog. 2019 10; 58(10):1754-1769.
    View in: PubMed
    Score: 0.054
  36. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. Immunity. 2019 05 21; 50(5):1317-1334.e10.
    View in: PubMed
    Score: 0.053
  37. Autophagy in 3D In Vitro and Ex Vivo Cancer Models. Methods Mol Biol. 2019; 1880:491-510.
    View in: PubMed
    Score: 0.052
  38. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019 01; 14(1):25-36.
    View in: PubMed
    Score: 0.051
  39. A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma. J Thorac Oncol. 2018 09; 13(9):1400-1409.
    View in: PubMed
    Score: 0.050
  40. Inhibition of autophagy initiation potentiates chemosensitivity in mesothelioma. Mol Carcinog. 2018 03; 57(3):319-332.
    View in: PubMed
    Score: 0.048
  41. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.048
  42. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
    View in: PubMed
    Score: 0.048
  43. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016 09 08; 1(14):e89014.
    View in: PubMed
    Score: 0.045
  44. Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Sci Rep. 2016 08 19; 6:31745.
    View in: PubMed
    Score: 0.044
  45. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. Mol Oncol. 2016 10; 10(8):1255-65.
    View in: PubMed
    Score: 0.044
  46. Autophagy initiation correlates with the autophagic flux in 3D models of mesothelioma and with patient outcome. Autophagy. 2016 07 02; 12(7):1180-94.
    View in: PubMed
    Score: 0.043
  47. Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma. PLoS One. 2016; 11(3):e0150044.
    View in: PubMed
    Score: 0.043
  48. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501.
    View in: PubMed
    Score: 0.043
  49. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2015 May; 149(5):1374-81.
    View in: PubMed
    Score: 0.040
  50. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013 Dec 20; 31(36):4544-9.
    View in: PubMed
    Score: 0.037
  51. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. AJR Am J Roentgenol. 2012 Feb; 198(2):359-63.
    View in: PubMed
    Score: 0.032
  52. Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. Ann Thorac Surg. 2011 Nov; 92(5):1819-23; discussion 1824-5.
    View in: PubMed
    Score: 0.032
  53. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg. 2010 Sep; 90(3):949-56; discussion 956.
    View in: PubMed
    Score: 0.029
  54. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg. 2010 Aug; 140(2):352-5.
    View in: PubMed
    Score: 0.029
  55. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):405-11.
    View in: PubMed
    Score: 0.027
  56. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009 Feb; 137(2):453-8.
    View in: PubMed
    Score: 0.026
  57. A gene expression ratio-based diagnostic test for bladder cancer. Adv Appl Bioinform Chem. 2009; 2:17-22.
    View in: PubMed
    Score: 0.026
  58. VATS pericardiotomy for patients with known malignancy and pericardial effusion: survival and prognosis of positive cytology and metastatic involvement of the pericardium: a case control study. Int J Surg. 2008 Apr; 6(2):110-4.
    View in: PubMed
    Score: 0.024
  59. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004 Jul; 128(1):138-46.
    View in: PubMed
    Score: 0.019
  60. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol. 2003 Aug; 29(2):157-62.
    View in: PubMed
    Score: 0.017
  61. Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. Lung Cancer. 2003 Jan; 39(1):23-9.
    View in: PubMed
    Score: 0.017
  62. Cardiac decortication (epicardiectomy) for occult constrictive cardiac physiology after left extrapleural pneumonectomy. Chest. 2002 Dec; 122(6):2256-9.
    View in: PubMed
    Score: 0.017
  63. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13790-5.
    View in: PubMed
    Score: 0.016
  64. Sequential thoracic metastasectomy prolongs survival by re-establishing local control within the chest. J Thorac Cardiovasc Surg. 2001 Apr; 121(4):657-67.
    View in: PubMed
    Score: 0.015
  65. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999 Jan; 117(1):54-63; discussion 63-5.
    View in: PubMed
    Score: 0.013
  66. No-cut thoracoscopic lung plication: a new technique for lung volume reduction surgery. J Am Coll Surg. 1997 Jul; 185(1):25-32.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.